Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non Operating Income (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Non Operating Income data on record, last reported at $2.7 million in Q3 2025.

  • For Q3 2025, Non Operating Income fell 0.8% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $13.4 million, up 34.78%, while the annual FY2024 figure was $11.0 million, 32.36% up from the prior year.
  • Non Operating Income reached $2.7 million in Q3 2025 per GLUE's latest filing, down from $4.5 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $4.5 million in Q2 2025 and bottomed at $1.6 million in Q4 2023.
  • Average Non Operating Income over 3 years is $2.7 million, with a median of $2.6 million recorded in 2024.
  • The widest YoY moves for Non Operating Income: up 72.52% in 2025, down 0.8% in 2025.
  • A 3-year view of Non Operating Income shows it stood at $1.6 million in 2023, then skyrocketed by 63.44% to $2.6 million in 2024, then rose by 4.62% to $2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $2.7 million in Q3 2025, $4.5 million in Q2 2025, and $3.7 million in Q1 2025.